drugset
drugset / Trial / NCT06536166

Ruxolitinib Treatment in Inclusion Body Myositis

NCT06536166 ↗

Phase 2 Recruiting 80 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Refer to the "Detailed Description" section.

Timeline

Start
2025-05-27
Primary completion
2028-06-10
Completion
2028-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 15 mg Oral

Indications

inclusion body myositis